Here are the top Institutional holders of Akebia Therapeutics Inc. (AKBA) shares

Akebia Therapeutics Inc. (NASDAQ: AKBA) is 31.45% higher on its value in year-to-date trading and has touched a low of $0.49 and a high of $1.84 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $1.65 in the last trading session, with the day’s loss setting it -0.02%.

Currently trading at $1.63, the stock is 4.55% and 21.33% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing -1.21% at the moment leaves the stock 37.94% off its SMA200. AKBA registered 44.25% gain for a year compared to 6-month gain of 7.95%. The firm has a 50-day simple moving average (SMA 50) of $1.64 and a 200-day simple moving average (SMA200) of $498.04.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 4.49% loss in the last 1 month and extending the period to 3 months gives it a 49.54%, and is -4.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.32% over the week and 7.28% over the month.

Akebia Therapeutics Inc. (AKBA) has around 205 employees, a market worth around $307.08M and $193.61M in sales. Profit margin for the company is -31.56%. Distance from 52-week low is 232.59% and -11.41% from its 52-week high. The company has generated returns on investments over the last 12 months (-99.37%).

Akebia Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $55.39M over the same period.The EPS is expected to grow by 39.71% this year, but quarterly earnings will post -33.70% year-over-year. Quarterly sales are estimated to grow 0.40% in year-over-year returns.

88 institutions hold shares in Akebia Therapeutics Inc. (AKBA), with institutional investors hold 27.66% of the company’s shares. The shares outstanding are 184.14M, and float is at 165.54M with Short Float at 4.73%. Institutions hold 26.84% of the Float.

The top institutional shareholder in the company is Alerce Investment Management, L.P. with over 16.21 million shares valued at $14.83 million. The investor’s holdings represent 8.61% of the AKBA Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 7.81 million shares valued at $7.15 million to account for 4.15% of the shares outstanding. The other top investors are Acadian Asset Management. LLC which holds 7.46 million shares representing 3.96% and valued at over $6.83 million, while Renaissance Technologies, LLC holds 1.77% of the shares totaling 3.33 million with a market value of $3.05 million.

Akebia Therapeutics Inc. (AKBA) Insider Activity

A total of 0 insider transactions have happened at Akebia Therapeutics Inc. (AKBA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Butler John P., the company’s CEO and President. SEC filings show that Butler John P. sold 46,489 shares of the company’s common stock on Feb 01 at a price of $1.68 per share for a total of $78102.0. Following the sale, the insider now owns 2.13 million shares.

Akebia Therapeutics Inc. disclosed in a document filed with the SEC on Feb 01 that Burke Steven Keith (SVP, Chief Medical Officer) sold a total of 24,311 shares of the company’s common stock. The trade occurred on Feb 01 and was made at $1.68 per share for $40842.0. Following the transaction, the insider now directly holds 0.71 million shares of the AKBA stock.

Still, SEC filings show that on May 25, Dahan Michel (SVP, Chief Operating Officer) disposed off 95,478 shares at an average price of $1.22 for $0.12 million. The insider now directly holds 574,037 shares of Akebia Therapeutics Inc. (AKBA).

Akebia Therapeutics Inc. (AKBA): Who are the competitors?

One of the company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -3.55% down over the past 12 months.Novartis AG ADR (NVS) lies in the list of competitors of the Akebia Therapeutics Inc. and is 23.86% higher over the same period from AKBAEnzon Pharmaceuticals Inc. (ENZN) is -66.75% down on the 1-year trading charts.